Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Source: spectrumnews.org
📰 Nova Menti News
Nova Menti News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nova Menti. Real-time updates on events, politics, business and more.
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
Wellbeing Digital Sciences Inc. , an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and... | April 18, 2023
Source: marketscreener.com
KGK Sciences receives approval for psilocybin clinical trial in Canada
KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder. According to a company press release, the results of a 10-person, open-label study will be used to support KGK’s client Nova Mentis’ drug development program under
Source: healio.com